Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.32 |
| ▸ | TAS2R46 | P59540 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28030332 | 0.83 | TAS2R46 (0.39) | CHRM2CHRM4CHRM1CHRM3LMNA | |
| SCHEMBL15462384 | 0.74 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL5930166 | 0.74 | APOBEC3A (0.34) | APOBEC3AAPOBEC3GLMNAALDH1A1POLB | |
| SCHEMBL28858253 | 0.72 | ACHE (0.37) | ALDH1A1 | |
| SCHEMBL8031761 | 0.71 | MEN1 (0.31) | ALDH1A1 | |
| SCHEMBL28129853 | 0.70 | CHRM2 (0.53) | CHRM2CHRM4CHRM1CHRM3APOBEC3A | |
| SCHEMBL2482943 | 0.70 | APOBEC3A (0.32) | APOBEC3AAPOBEC3GLMNAALDH1A1POLB | |
| SCHEMBL22832664 | 0.69 | ALDH1A1 (0.34) | APOBEC3AAPOBEC3GLMNAALDH1A1POLB | |
| SCHEMBL28025682 | 0.69 | CHRM2 (0.41) | CHRM2CHRM4CHRM1CHRM3LMNA | |
| SCHEMBL29315039 | 0.68 | CHRM2 (0.47) | CHRM2CHRM4CHRM1CHRM3APOBEC3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113316398-B | Seamless capsule, filter and smoking article comprising same | 三生医药株式会社 | 2024-06-11 | — | — | CN | disclosed |
| CN-118159258-A | Composition containing caryophyllene | 三生医药株式会社 | 2024-06-07 | — | — | CN | disclosed |
| CN-117120042-A | Seamless capsule capable of stably disintegrating even in high-temperature and high-humidity environment and method for producing same | 森下仁丹株式会社 | 2023-11-24 | — | — | CN | disclosed |
| US-20230200435-A1 | CARYOPHYLLENE-CONTAINING AGENT OR COMPOSITION AND VARIOUS APPLICATIONS THEREOF | KINKI UNIVERSITY (JP) | 2023-06-29 | — | — | US | disclosed |
| CN-113316398-A | Seamless capsule, filter and smoking article comprising same | 三生医药株式会社 | 2021-08-27 | — | — | CN | disclosed |
| US-10015984-B2 | Disintegrable capsule, manufacturing method for same, and smoking device containing said disintegrable capsule | SUNSHO PHARMACEUTICAL CO., LTD. (JP) | 2018-07-10 | — | — | US | disclosed |
| EP-2997837-A1 | DISINTEGRABLE CAPSULE, MANUFACTURING METHOD FOR SAME, AND SMOKING EQUIPMENT CONTAINING SAID DISINTEGRABLE CAPSULE | Sunsho Pharmaceutical Co., Ltd. (JP) | 2016-03-23 | — | — | EP | disclosed |
| CN-103732060-B | Antimicrobial compositions | TAKASAGO INTERNATIONAL CORP. (JP) | 2016-02-17 | — | — | CN | disclosed |
| US-20160021927-A1 | DISINTEGRABLE CAPSULE, MANUFACTURING METHOD FOR SAME, AND SMOKING EQUIPMENT CONTAINING SAID DISINTEGRABLE CAPSULE | SUNSHO PHARMACEUTICAL CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20140163099-A1 | ANTIMICROBIAL COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-06-12 | — | — | US | disclosed |
| EP-2725900-A1 | ANTIMICROBIAL COMPOSITION | Takasago International Corporation (JP) | 2014-05-07 | — | — | EP | disclosed |
| CN-102357061-B | Fragrance composition | KAO CORP | 2013-09-04 | — | — | CN | disclosed |
| WO-2013002421-A1 | ANTIMICROBIAL COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-01-03 | — | — | WO | disclosed |
| US-20130005807-A1 | ANTIMICROBIAL COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-01-03 | — | — | US | disclosed |
| US-7964637-B2 | Process for producing optically active theaspirane | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| CN-101579292-A | Perfume composition | KAO CORP (JP) | 2009-11-18 | — | — | CN | disclosed |
| US-20090270516-A1 | Process for Producing Optically Active Theaspirane | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-10-29 | — | — | US | disclosed |
| CN-100522127-C | Perfume composition | KAO CORP (JP) | 2009-08-05 | — | — | CN | disclosed |
| CN-1674862-A | Perfume composition | KAO CORP (JP) | 2005-09-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270516-A1 | Process for Producing Optically Active Theaspirane | DHPS, ALDH7A1, FASN | CHRM2 4303/4885CHRM4 3819/4885CHRM1 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.